NCT04413227View on ClinicalTrials.gov

A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 2, 2020

Primary Completion Date

May 31, 2021

Study Completion Date

September 30, 2021

Conditions
NSCLCSolid Tumor
Interventions
DRUG

Pegylated Recombinant Human Endostatin（PEG-ENDO）

PEG-ENDO 1 mg/kg or 2 mg/kg or 4 mg/kg or 6 mg/kg or 8 mg/kg+Docetaxel 75 mg/m2，once every 3 weeks at day 1

Trial Locations (2)

100005

NOT_YET_RECRUITING

Beijing Hospital, Beijing

300060

RECRUITING

Tianjin medical university cancer institute&hospital, Tianjin

Sponsors
All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY

NCT04413227 - A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors | Biotech Hunter | Biotech Hunter